Craig Hildreth, MD
Medical Oncology · Saint Louis, MONPI 1851393136
Payments from drug & device makers
Across 211 payments — averaging $51.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- Genentech USA, Inc.$311
- Amgen$227
- Bristol Myers Squibb$218
- AbbVie$217
- Novartis$215
- plus $3K from 35 others
What the payments were for
- Consulting fees$5,70053%
- Travel & lodging$1,04710%
- Food & beverage$3,93036%
- Education$1421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 21 | $6,959 |
| Genentech USA, Inc. | 17 | $311 |
| Amgen | 12 | $227 |
| Bristol Myers Squibb | 19 | $218 |
| AbbVie | 7 | $217 |
| Novartis | 13 | $215 |
| AstraZeneca | 7 | $172 |
| Gilead | 6 | $169 |
| Myriad Genetic Laboratories, Inc. | 3 | $168 |
| Johnson & Johnson | 12 | $164 |
| Pfizer | 11 | $163 |
| Lilly USA, LLC | 9 | $150 |
| Beone Medicines USA, Inc. | 1 | $148 |
| Boehringer Ingelheim | 7 | $137 |
| Incyte Corporation | 8 | $128 |
| Coherus Oncology, Inc. | 5 | $122 |
| Eisai Inc. | 7 | $117 |
| Genmab U.S., Inc. | 2 | $116 |
| Regeneron Healthcare Solutions, Inc. | 1 | $102 |
| Sanofi | 5 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $74 |
| EMD Serono, Inc. | 4 | $72 |
| Lexicon Pharmaceuticals, Inc. | 1 | $67 |
| Astellas Pharma US Inc | 4 | $63 |
| Exelixis Inc. | 3 | $59 |
| Merck | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Taiho Oncology, Inc. | 2 | $34 |
| Intrinsiq Specialty Solutions, Inc. | 1 | $29 |
| Seagen Inc. | 2 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Secura Bio, Inc. | 1 | $22 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Verastem, Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,819 in reported general payments places this provider in the 35th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 80 | $1,396,448 |
| CalquenceAcalabrutinib Maleate | 63 | $955,174 |
| KisqaliRibociclib Succinate | 51 | $821,895 |
| TibsovoIvosidenib | 25 | $802,135 |
| LenvimaLenvatinib Mesylate | 22 | $513,202 |
| IbrancePalbociclib | 27 | $425,286 |
| JaypircaPirtobrutinib | 14 | $301,510 |
| BrukinsaZanubrutinib | 23 | $294,949 |
| PomalystPomalidomide | 15 | $253,042 |
| ImbruvicaIbrutinib | 15 | $226,440 |
| Lenalidomide | 16 | $208,315 |
| VenclextaVenetoclax | 13 | $178,019 |
| Abiraterone Acetate | 64 | $23,369 |
| EliquisApixaban | 30 | $22,036 |
| OxycontinOxycodone Hcl | 13 | $5,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $218 | $1,396,44880 claims |
| AstraZenecaCalquence | $172 | $955,17463 claims |
| NovartisKisqali | $215 | $821,89551 claims |
| Eisai Inc.Lenvima | $117 | $513,20222 claims |
| PfizerIbrance, Eliquis | $163 | $447,32257 claims |
| Lilly USA, LLCJaypirca | $150 | $301,51014 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $6,959 | $253,04215 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $74 | $226,44015 claims |
| AbbVieVenclexta | $217 | $178,01913 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $18 | $1,03553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
- Russell PachynskiSaint Louis$8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.